Transine Therapeutics, a Cambridge UK-based biotechnology company which specializes in development of therapeutic RNAs, closed £9.1 in funding.
The round was led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF). In conjunction with the financing, Rob Woodman, Senior Partner at Takeda Ventures, and Christian Jung, Partner at the DDF joined Transine’s Board.
The company intends to use the funds to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics, initially focused on the Central Nervous System and Ophthalmology applications.
Founded in 2020, Transine Therapeutics is a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology. Transine is based on the work of geneticists Professors Stefano Gustincich and Piero Carninci, who identified a new functional and naturally occurring class of long non-coding RNAs, named SINEUPs. The technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.